ADC Therapeutics Expands Team
News Oct 08, 2014
ADC Therapeutics has announced a significant expansion of its team as the Company’s first ADCs enter clinical development.
New team members include:
• Dr Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. Dr Feingold has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he served as Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth.
• Dr Michael Mulkerrin joins as Head of CMC (Chemistry Manufacturing and Control). Dr Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech.
• Dr Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis and has had prior senior roles at AstraZeneca, Syngenta and Quintiles.
• Dr Lisa Skelton joins as Senior Project Manager for ADCT’s lead program ADCT-301 which is scheduled to enter clinical development in early 2015. Dr. Skelton has over 20 years of industry experience, most recently as Associate Director, Programme Management at Norgine and Senior Program Manager at Amgen.
• Dr Karin Havenith joins as Senior Bioanalytical Scientist to head ADCT’s bioanalytical group. Dr. Havenith was Principal Scientist at J&J Janssen Crucell and Principal Scientist at Genmab where she specialized in the development of bioanalytical assays for antibody therapeutics.
• Dr Francesca Zammarchi joins the scientific team as Cancer Biologist, having spent eight years as a Research Associate in the Molecular Pharmacology and Chemistry Department of Memorial Sloan Kettering Cancer Center, New York.
• Ms. Dulce Gonçalves joins to serve as Corporate Counsel. Ms Gonçalves has over 12 years experience in pharmaceutical law and was most recently Senior Legal Counsel, Global Product Strategy and Commercialization, at Novartis.
• Mr. Stéphane Henchoz joins as Director of Finance, bringing more than 20 years pharmaceutical industry finance experience, most recently working at Merck Serono.
Michael Forer, Chief Executive Officer of ADC Therapeutics, said: “The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs. This expansion underlines the progress we have made since the Company was established in early 2012. We continue to advance our pipeline of programs into clinical development with our lead program, ADCT-301, scheduled to enter clinical development in early 2015.”
Dr. Peter B. Corr, Chairman of the Board and co-founder and Managing General Partner of ADCT’s founding majority investor, Auven Therapeutics, added “ADCs are an important class of the next-generation of cancer drugs, and with our best in class PBD warheads and linkers these agents should have a profound impact for patients with cancer. With the addition over the last year of AstraZeneca, as both an investor in and corporate partner of ADCT, the Company is well funded, and with these new personnel now has a world class team in place to support our plan of having multiple proprietary ADCs in clinical development over the coming two years.”
Cellular Valve Structure Opens Up Potential Novel TherapiesNews
Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.READ MORE
Stem Cell Signaling Drives Mammary Gland DevelopmentNews
New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.READ MORE
Inflammatory Bowel Disease Linked with Common Bacterial Gut ToxinNews
New research has uncovered a surprise link between a common bacterial toxin found in the gut and inflammatory bowel disease (IBD). It shows that breakdown products from the toxin seem to trigger gut inflammation that is characteristic of IBD.READ MORE